What the New Guidance Says
A recent analysis published in Psychiatric Times outlines how clinicians are currently navigating treatment selection for treatment-resistant depression (TRD) — a condition affecting millions of Americans who have not responded to two or more adequate antidepressant trials. The piece highlights the growing role of fast-acting glutamatergic interventions, including esketamine (Spravato) and IV ketamine, alongside brain stimulation therapies like TMS and ECT, as frontline options when standard antidepressants fall short.
What's notable in 2026 is the explicit acknowledgment that patient preference, functional outcomes, and speed of response are now central to how clinicians make these calls — not just symptom checklists. That shift matters enormously for people who have spent years cycling through medications with little relief and are now exploring ketamine-based care.
Ketamine and Esketamine: Where They Fit
The guidance reinforces what clinical practice has been moving toward for several years: glutamate-targeting treatments like ketamine and its FDA-approved derivative esketamine occupy a distinct and important lane in TRD care. Unlike traditional antidepressants that can take four to six weeks to show meaningful effect, ketamine-based treatments can produce measurable improvements in mood and function within hours to days. For patients in acute distress or those who have lost significant quality of life to depression, that speed of action is clinically and personally significant.
The distinction between IV ketamine and intranasal esketamine (Spravato) is worth understanding as a patient. Esketamine carries FDA approval specifically for TRD and is administered in certified healthcare settings with a mandatory observation period. IV ketamine, while used extensively off-label, is delivered through a broader range of clinic types — including, increasingly, telehealth-connected providers who coordinate infusion care or offer oral ketamine protocols. Both approaches are represented in the telehealth ketamine landscape, and the Psychiatric Times analysis affirms that both belong in a serious clinical conversation about TRD.
Brain stimulation therapies — TMS, ECT, and newer options like MST — are also discussed as alternatives or complements, particularly for patients who have not responded to pharmacological approaches. For those considering ketamine through an online provider, it's worth knowing where ketamine fits in this broader treatment hierarchy: it is not a last resort, but it is typically considered after at least two antidepressant failures, which aligns with standard TRD criteria used by reputable telehealth ketamine services.
Key Takeaway for Patients
If you're exploring online ketamine treatment for depression, ask your prospective provider how they assess TRD eligibility and what their protocol looks like if ketamine doesn't produce the expected response. Reputable telehealth ketamine services should have a clear answer — including pathways to escalated or alternative care. A provider who treats ketamine as a standalone solution rather than part of a broader treatment plan is a red flag worth taking seriously.
What This Means for Patients Considering Telehealth Ketamine
The clinical framework described in this guidance has direct implications for how you should evaluate online ketamine providers. The emphasis on patient preference and functional outcomes — not just symptom reduction — reflects a more sophisticated standard of care. When you're vetting a telehealth ketamine service, look for providers who ask not just whether you feel depressed, but how depression is affecting your work, relationships, sleep, and daily function. That breadth of assessment signals a clinician operating at a higher standard.
The guidance also underscores the importance of individualized treatment planning. TRD is not a monolithic condition, and the right intervention depends on a patient's history, comorbidities, prior treatment responses, and personal circumstances. A telehealth intake process that takes 10 minutes and asks only basic screening questions is unlikely to produce the kind of individualized plan this guidance describes as best practice. Thorough psychiatric evaluation — even conducted remotely — should take time and cover meaningful ground.
For patients in states with broader telehealth prescribing access, oral ketamine protocols (typically sublingual troches or rapid-dissolve tablets) have made at-home ketamine treatment a genuine option. These protocols vary significantly in quality. The clinical literature increasingly supports the value of integration — meaning therapy, follow-up appointments, and structured support alongside the ketamine sessions themselves. Providers who offer only the medication without structured follow-up care are leaving a significant part of the therapeutic value on the table.
Cost remains a practical barrier. Neither IV ketamine nor most oral ketamine protocols are consistently covered by insurance, and esketamine (Spravato), while FDA-approved, requires in-office administration that adds logistical complexity. Out-of-pocket costs for a full ketamine treatment course through a telehealth provider typically range from several hundred to several thousand dollars depending on the protocol and level of clinical support included. Understanding what you're paying for — and what follow-up is included — before committing is essential.
The broader takeaway from this clinical guidance is that TRD treatment in 2026 is more personalized, faster-acting, and option-rich than it was a decade ago. Ketamine is a legitimate, evidence-supported part of that picture. But the quality of the experience depends heavily on the provider. Use the clinical standards described in guidance like this as your benchmark — and don't settle for a telehealth service that can't meet them.
Source: Psychiatric Times — Factors Guiding Treatment Selection in Treatment Resistant Depression
Share